Short Interest in InflaRx N.V. (NASDAQ:IFRX) Rises By 203.1%

InflaRx N.V. (NASDAQ:IFRX) was the target of a significant growth in short interest in the month of May. As of May 15th, there was short interest totaling 6,039,577 shares, a growth of 203.1% from the April 30th total of 1,992,416 shares. Based on an average trading volume of 4,655,170 shares, the days-to-cover ratio is presently 1.3 days. Approximately 10.0% of the shares of the company are short sold.

Institutional Investors Weigh In On InflaRx

Several institutional investors and hedge funds have recently bought and sold shares of IFRX. Bank of America Corp DE bought a new stake in InflaRx in the 3rd quarter valued at $3,316,000. Suvretta Capital Management LLC increased its holdings in InflaRx by 22.4% in the 4th quarter. Suvretta Capital Management LLC now owns 7,933,910 shares of the company’s stock valued at $8,013,000 after buying an additional 1,450,000 shares during the period. 683 Capital Management LLC increased its holdings in InflaRx by 47.3% in the 4th quarter. 683 Capital Management LLC now owns 3,315,000 shares of the company’s stock valued at $3,348,000 after buying an additional 1,065,000 shares during the period. Woodline Partners LP bought a new stake in InflaRx in the 1st quarter valued at $766,000. Finally, Adage Capital Partners GP L.L.C. bought a new stake in InflaRx in the 2nd quarter valued at $262,000. Institutional investors own 42.39% of the company’s stock.

InflaRx Trading Up 0.8%

Shares of IFRX stock opened at $2.40 on Friday. InflaRx has a 1 year low of $0.74 and a 1 year high of $2.95. The firm’s fifty day simple moving average is $1.69 and its 200 day simple moving average is $1.26. The firm has a market capitalization of $173.50 million, a P/E ratio of -3.38 and a beta of 2.42.

InflaRx (NASDAQ:IFRX) last announced its quarterly earnings results on Thursday, May 7th. The company reported ($0.09) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.17) by $0.08. Equities research analysts anticipate that InflaRx will post -0.51 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on IFRX shares. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of InflaRx in a research report on Friday, March 27th. Raymond James Financial raised shares of InflaRx from an “outperform” rating to a “strong-buy” rating and boosted their target price for the stock from $7.00 to $9.00 in a research report on Wednesday, May 13th. Guggenheim reaffirmed a “buy” rating and set a $14.00 target price on shares of InflaRx in a research report on Tuesday, April 21st. Oppenheimer started coverage on shares of InflaRx in a research report on Friday, April 24th. They set an “outperform” rating and a $5.00 target price on the stock. Finally, Wall Street Zen raised shares of InflaRx from a “sell” rating to a “hold” rating in a research report on Saturday, May 9th. One equities research analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus target price of $7.00.

InflaRx Company Profile

InflaRx N.V. is a clinical‐stage biopharmaceutical company focused on the discovery, development and commercialization of novel therapies targeting the complement system, with an emphasis on the complement‐1a (C5a) pathway. The company’s lead product candidate, vilobelimab (IFX‐1), is a monoclonal antibody designed to selectively inhibit C5a, a potent pro‐inflammatory peptide implicated in a range of autoimmune and inflammatory diseases. InflaRx seeks to address high‐unmet medical needs by advancing treatments for conditions such as hidradenitis suppurativa, pyoderma gangrenosum and other rare and severe inflammatory disorders.

Vilobelimab has been evaluated in multiple Phase II trials, demonstrating proof of concept in reducing key inflammatory markers and improving clinical outcomes.